This is the classic website, which will be retired eventually. Please visit the modernized ClinicalTrials.gov instead.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05789069
Recruitment Status : Recruiting
First Posted : March 29, 2023
Last Update Posted : December 4, 2023
Sponsor:
Information provided by (Responsible Party):
HiFiBiO Therapeutics

Brief Summary:
The purpose of this study is to test the safety and tolerability of HFB200603 as a single agent and in combination with tislelizumab in patients with advanced cancers. There are two parts in this study. During the escalation part, groups of participants will receive increasing doses of HFB200603 as a monotherapy or in combination with tislelizumab until a safe and tolerable dose of HFB200603 as a single agent or combination therapy is determined. During the expansion part, participants will take the doses of HFB200603 as a monotherapy (optional arm) or in combination with tislelizumab that were determined from the escalation part of the study and will be assigned to a group based on the type of cancer the participants have.

Condition or disease Intervention/treatment Phase
Renal Cell Carcinoma Melanoma Non Small Cell Lung Cancer Gastric Cancer Colorectal Cancer Drug: HFB200603 Drug: Tislelizumab Phase 1

Detailed Description:

This is a Phase 1a/b, first in human, open-label, dose escalation and expansion study in adults with advanced cancers. The study will comprise of

  1. A Screening Period of up to 28 days
  2. A Treatment Period during which participants will receive the study drug on the first day of each cycle where each cycle is 21 days. Number of cycles depends on how the disease responds to the study drug
  3. A Follow-up Period which involves 2 visits

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 83 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1a/1b, Open-Label, Multi-Center, Dose Escalation and Expansion Study of HFB200603 (Anti-BTLA Antibody) as a Single Agent and in Combination With Tislelizumab (Anti-PD-1 Antibody) in Adult Patients With Advanced Solid Tumors
Actual Study Start Date : May 9, 2023
Estimated Primary Completion Date : December 2025
Estimated Study Completion Date : December 2025


Arm Intervention/treatment
Experimental: Dose Escalation - HFB200603 monotherapy
Participants will be administered HFB200603 at dose levels 1-4 as an intravenous infusion to determine the Recommended Dose for Expansion (RDE).
Drug: HFB200603
Participants will be administered HFB200603 as described in the experimental arm.

Experimental: Dose Escalation - HFB200603 in combination with tislelizumab
Participants will be administered HFB200603 at dose levels 1-3 in combination with one dose level of tislelizumab as an intravenous infusion to determine the combination Recommended Doses for Expansion (RDEs).
Drug: HFB200603
Participants will be administered HFB200603 as described in the experimental arm.

Drug: Tislelizumab
Participants will be administered tislelizumab as described in the experimental arm.
Other Name: BGB-A317

Experimental: Dose Expansion - HFB200603 monotherapy (optional)
Participants will be administered HFB200603 at monotherapy RDE as an intravenous infusion.
Drug: HFB200603
Participants will be administered HFB200603 as described in the experimental arm.

Experimental: Dose Expansion - HFB200603 in combination with tislelizumab
Participants will be administered HFB200603 in combination with tislelizumab at combination RDEs as an intravenous infusion. Based on the cancer type, participants will be randomized to combination HFB200603 RDE 1 or RDE 2.
Drug: HFB200603
Participants will be administered HFB200603 as described in the experimental arm.

Drug: Tislelizumab
Participants will be administered tislelizumab as described in the experimental arm.
Other Name: BGB-A317




Primary Outcome Measures :
  1. Number of participants with adverse events (AEs) meeting protocol-defined Dose-Limiting Toxicity (DLT) criteria during Dose Escalation [ Time Frame: The first cycle of treatment (Day 1 up to Day 21) ]
    Severity of adverse events will be based on common terminology criteria for adverse events (CTCAE) version 5.0

  2. Number of participants with AEs [ Time Frame: Cycle 1 Day 1 to 90 days after the last dose of study drug(s) (each cycle is 21 days), assessed up to 3 years ]
    Severity of AEs will be assessed based on CTCAE version 5.0 (except for cytokine release syndrome which will be assessed by American Society for Transplantation and Cellular Therapy grading)

  3. Number of participants with changes in laboratory values [ Time Frame: Cycle 1 Day 1 to 90 days after the last dose of study drug(s) (each cycle is 21 days), assessed up to 3 years ]
  4. Number of participants with changes in vital signs [ Time Frame: Cycle 1 Day 1 to 90 days after the last dose of study drug(s) (each cycle is 21 days), assessed up to 3 years ]
  5. Number of participants with changes in electrocardiogram (ECG) [ Time Frame: Cycle 1 Day 1 to 90 days after the last dose of study drug(s) (each cycle is 21 days), assessed up to 3 years ]
  6. Number of participants with changes in tolerability (dose interruptions and dose intensity) [ Time Frame: Cycle 1 Day 1 to 90 days after the last dose of study drug(s) (each cycle is 21 days), assessed up to 3 years ]
  7. To determine a Recommended Phase 2 Dose (RP2D) during Dose Expansion [ Time Frame: Cycle 1 Day 1 to 90 days after the last dose of study drug(s) (each cycle is 21 days), assessed up to 3 years ]

Secondary Outcome Measures :
  1. Objective Response Rate (ORR) as determined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and immune-RECIST (iRECIST) [ Time Frame: Baseline to 90 days after the last dose of study drug(s) (each cycle is 21 days), assessed up to 3 years ]
  2. Disease Control Rate (DCR) as determined by RECIST 1.1 and iRECIST [ Time Frame: Baseline to 90 days after the last dose of study drug(s) (each cycle is 21 days), assessed up to 3 years ]
  3. Duration of Response (DOR) as determined by RECIST 1.1 and iRECIST [ Time Frame: Start of first response to first date of disease progression, clinical progression or death, whichever occurs first, assessed up to 3 years ]
  4. Progression Free Survival (PFS) as determined by RECIST 1.1 and iRECIST [ Time Frame: Baseline to disease progression or death, whichever occurs first, assessed up to 3 years ]
  5. Minimum serum concentration (Cmin) [ Time Frame: Cycle 1 Day 1 to day of the last dose of study drug(s) (each cycle is 21 days), through study completion, an average of 3 year ]
  6. Maximum serum concentration (Cmax) [ Time Frame: Cycle 1 Day 1 to day of the last dose of study drug(s) (each cycle is 21 days), through study completion, an average of 3 year ]
  7. Area under the concentration versus time curve (AUC) [ Time Frame: Cycle 1 Day 1 to day of the last dose of study drug(s) (each cycle is 21 days), through study completion, an average of 3 year ]
  8. Terminal half-life (T1/2) [ Time Frame: Cycle 1 Day 1 to day of the last dose of study drug(s) (each cycle is 21 days), through study completion, an average of 3 year ]
  9. Serum concentration for measurement of anti-HFB200603 antibodies [ Time Frame: Cycle 1 Day 1 to day of the last dose of study drug(s) (each cycle is 21 days), through study completion, an average of 3 year ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patient must have one of the following cancers and previously received the following lines of systemic therapy for the advanced/metastatic disease:

    • Renal cell carcinoma: at least 2 lines of therapy
    • Non-small cell lung cancer: at least 2 lines of therapy
    • Melanoma:

      • BRAF V600E positive: must have received at least 2 lines of therapy
      • BRAF V600E negative: must have received at least 1 line of therapy
    • Gastric cancer: at least 1 line of therapy
    • Colorectal cancer: at least 3 lines of therapy
  • Suitable site to biopsy at pre-treatment and on-treatment
  • Measurable disease as determined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
  • Eastern Cooperative Oncology Group performance status of 0 or 1

Exclusion Criteria:

  • Systemic anti-cancer therapy within 2 weeks prior to start of study drug or within 4 weeks for immune-oncologic therapy. For cytotoxic agents with major delayed toxicity (e.g., mitomycin C), 6 weeks of washout are mandated.
  • Therapeutic radiation therapy within the past 2 weeks
  • Active autoimmune diseases or history of autoimmune disease that may relapse
  • Any malignancy ≤ 5 years before first dose of study drug except for the specific cancer under investigation in this study and any locally recurring cancer that has been treated curatively
  • Systemic steroid therapy (>10 mg/day of prednisone or equivalent) or any immune suppressive medication ≤ 14 days before first dose
  • Patients with toxicities (as a result of prior anticancer therapy) which have not recovered to baseline or stabilized, except for adverse events not considered a likely safety risk (e.g., alopecia, neuropathy, and specific laboratory abnormalities)
  • Severe or unstable medical condition, including uncontrolled diabetes, coagulopathy, or unstable psychiatric condition
  • Major surgery within 28 days of the first dose of study drug
  • History of interstitial lung disease, non-infectious pneumonitis, or uncontrolled lung diseases including pulmonary fibrosis or acute lung diseases. For combination only: non-small cell lung cancer patients, or patients with significantly impaired pulmonary function or who require supplemental oxygen at baseline must undergo an assessment of pulmonary function at screening
  • History of allergic reactions, immune related reactions, or cytokine release syndrome (CRS) attributed to compounds of similar chemical or biologic composition to monoclonal antibodies or any excipient of HFB200603 or tislelizumab
  • For combination only: Prior randomization in a tislelizumab study regardless of the treatment arm, until the primary and key secondary endpoints of the study have read out

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05789069


Contacts
Layout table for location contacts
Contact: Edward Steele, Clinical Trial Manager (513)579-9911 e.steele@medpace.com

Locations
Layout table for location information
United States, California
USC Norris Comprehensive Cancer Center Recruiting
Los Angeles, California, United States, 90033
United States, Pennsylvania
Fox Chase Cancer Center Recruiting
Philadelphia, Pennsylvania, United States, 19111
United States, Virginia
New Experimental Therapeutics of Virginia - NEXT Oncology Recruiting
Fairfax, Virginia, United States, 22031
Italy
Istituto Nazionale Tumori IRCCS Fondazione G. Pascale Recruiting
Napoli, Italy, 80131
UOC Fase I - Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore Recruiting
Rome, Italy, 00168
Centro Ricerche Cliniche di Verona s.r.l. Recruiting
Verona, Italy, 37134
Spain
Clinica Universidad de Navarra - Madrid Recruiting
Madrid, Spain, 28027
South Texas Accelerated Research Therapeutics (START) Madrid - Hospital Fundacion Jimenez Diaz Recruiting
Madrid, Spain, 28040
South Texas Accelerated Research Therapeutics (START) Madrid - CIOCC Recruiting
Madrid, Spain, 28050
Clinica Universidad de Navarra - Pamplona Recruiting
Pamplona, Spain, 31008
Hospital Clinico Universitario de Valencia Recruiting
Valencia, Spain, 46010
Sponsors and Collaborators
HiFiBiO Therapeutics
Layout table for additonal information
Responsible Party: HiFiBiO Therapeutics
ClinicalTrials.gov Identifier: NCT05789069    
Other Study ID Numbers: HFB-200603-01
First Posted: March 29, 2023    Key Record Dates
Last Update Posted: December 4, 2023
Last Verified: November 2023

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Renal Cell
Neoplasms by Site
Neoplasms
Neoplasms by Histologic Type
Adenocarcinoma
Carcinoma
Neoplasms, Glandular and Epithelial
Kidney Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Female Urogenital Diseases
Female Urogenital Diseases and Pregnancy Complications
Urogenital Diseases
Kidney Diseases
Urologic Diseases
Male Urogenital Diseases
Tislelizumab
Antineoplastic Agents, Immunological
Antineoplastic Agents